Global Atopic Dermatitis Drugs Market 2017-2021

アトピー性皮膚炎治療薬の世界市場2017-2021

◆タイトル:Global Atopic Dermatitis Drugs Market 2017-2021
◆商品コード:IRTNTR11179
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年1月24日
◆ページ数:68
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,500 ⇒換算¥495,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、アトピー性皮膚炎治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、アトピー性皮膚炎治療薬の世界市場規模及び予測、地域別分析/市場規模、ROA別分析、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況などの情報をお届けいたします。

About Atopic Dermatitis Drugs
Atopic dermatitis is a common, chronic, relapsing, inflammatory disease that primarily affects young children. Atopy refers to an inherited tendency to produce IgE antibodies, whereas, dermatitis means inflammation of the skin. Atopic dermatitis is associated with asthma, inhalant allergies (hay fever), and chronic dermatitis. In this condition, the skin becomes extremely itchy and inflamed, which causes redness, cracking, weeping, swelling, vesicle formation, crushing, and scaling. Atopic dermatitis is very common worldwide, and its prevalence rate is increasing. The data estimates suggest that nearly 60% of the patients develop symptoms in the first year of life, and 88%-92% develop symptoms before the age of five.

Technavio’s analysts forecast the global atopic dermatitis drugs market to grow at a CAGR of 4.20% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global atopic dermatitis drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of atopic dermatitis drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Atopic Dermatitis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• LEO Pharma
• Mylan
• Valeant
• Bayer HealthCare
• Encore Dermatology

[Market driver]
• Growing prevalence of food allergies exacerbating atopic dermatitis
• For a full, detailed list, view our report

[Market challenge]
• Poor patient adherence due to inadequate information on drug usage
• For a full, detailed list, view our report

[Market trend]
• Increasing M&A leading to market consolidation
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Key market highlights

PART 05: An overview of atopic dermatitis

PART 06: Pipeline analysis

PART 07: Market landscape
• Market overview
• Market size and forecast

PART 08: Five force analysis

PART 09: Market segment by ROA
• Oral ROA
• Topical ROA
• Injectable ROA

PART 10: Geographical segmentation
• Atopic dermatitis drugs market in Americas
• Atopic dermatitis drug market in EMEA
• Atopic dermatitis drugs market in APAC

PART 11: Market drivers
• Growing prevalence of food allergies exacerbating atopic dermatitis
• Growing focus on systemic therapies
• Increasing use of pharmacological products in developing countries

PART 12: Impact of drivers

PART 13: Market challenges
• Black box warning for Elidel and Protopic
• Highly genericized market
• Poor patient adherence due to inadequate information on drug usage

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Increasing M&A leading to market consolidation
• Launch of first biologic for atopic dermatitis
• Growing focus on novel drugs

PART 16: Vendor landscape
• Competitive scenario
• LEO Pharma
• Mylan
• Valeant
• Bayer HealthCare
• Encore Dermatology

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Global atopic dermatitis drugs market: Key customer segments
Exhibit 02: Pipeline analysis by phase 2016
Exhibit 03: Key pipeline molecules
Exhibit 04: Global atopic dermatitis drugs market: Snapshot
Exhibit 05: Global atopic dermatitis drugs market 2016-2021 ($ millions)
Exhibit 06: Global atopic dermatitis drugs market: Opportunity analysis
Exhibit 07: Five force analysis
Exhibit 08: Global atopic dermatitis drug market by ROA 2016
Exhibit 09: Oral ROA for atopic dermatitis
Exhibit 10: Global atopic dermatitis drugs market by geography 2016
Exhibit 11: Global atopic dermatitis drugs market by geography 2021
Exhibit 12: Market scenario: Americas
Exhibit 13: Atopic dermatitis drugs market in Americas 2016-2021 ($ millions)
Exhibit 14: Market scenario: EMEA
Exhibit 15: Atopic dermatitis drugs market in EMEA 2016-2021 ($ millions)
Exhibit 16: Market scenario in APAC
Exhibit 17: Atopic dermatitis drugs market in APAC 2016-2021 ($ millions)
Exhibit 18: Systemic therapy for atopic dermatitis.
Exhibit 19: Impact of drivers
Exhibit 20: Impact of drivers and challenges
Exhibit 21: New and emerging treatments for atopic dermatitis: Agents in Phase II clinical trials.
Exhibit 22: Global atopic dermatitis drugs market: Competitive structure analysis 2016
Exhibit 23: Competitive analysis of global atopic dermatitis drugs market
Exhibit 24: Market penetration of vendors in global atopic dermatitis drug market 2016
Exhibit 25: LEO Pharma: Key highlights
Exhibit 26: LEO Pharma: Strength assessment
Exhibit 27: LEO Pharma: Strategy assessment
Exhibit 28: LEO Pharma: Opportunity assessment
Exhibit 29: LEO Pharma: YoY revenue and growth rate of Protopic 2014-2016 ($ million)
Exhibit 30: Mylan: Key highlights
Exhibit 31: Mylan: Strength assessment
Exhibit 32: Mylan: Strategy assessment
Exhibit 33: Mylan: Opportunity assessment
Exhibit 34: Valeant: Key highlights
Exhibit 35: Valeant: Strength assessment
Exhibit 36: Valeant: Strategy assessment
Exhibit 37: Valeant: Opportunity assessment
Exhibit 38: Bayer HealthCare: Key highlights
Exhibit 39: Bayer HealthCare: Strength assessment
Exhibit 40: Bayer HealthCare: Strategy assessment
Exhibit 41: Bayer HealthCare: Opportunity assessment
Exhibit 42: Encore Dermatology: Key highlights
Exhibit 43: Encore Dermatology: Strength assessment
Exhibit 44: Encore Dermatology: Strategy assessment



【掲載企業】

LEO Pharma, Mylan, Valeant, Bayer HealthCare, Encore Dermatology.

【資料のキーワード】

アトピー性皮膚炎、アトピー性皮膚炎治療薬、食品アレルギー、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[アトピー性皮膚炎治療薬の世界市場2017-2021] (Global Atopic Dermatitis Drugs Market 2017-2021 / IRTNTR11179)販売に関する免責事項
[アトピー性皮膚炎治療薬の世界市場2017-2021] (Global Atopic Dermatitis Drugs Market 2017-2021 / IRTNTR11179)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆